in this issue

from the editor

What are going to be the big headlines for 2012? What will be the impact of Bydureon, the latest once-weekly drug for people with type 2 diabetes?

It’s been a busy month for the FDA – they approved Bydureon, the first once-weekly diabetes medication as well as the iBGStar, the first blood glucose meter that directly connects to an iPhone. But they didn’t approve dapagliflozin – the first of a new class of important drugs. What’s really going on in Washington?

thinking like a pancreas

Want faster acting insulin? CDE Gary Scheiner shows you some options with five innovative tips that you and your healthcare team may want to consider…

learning curve

What will it take to get an artificial pancreas approved? It seems that the path ahead may now be a bit clearer…

conference pearls

To the gym or to the pharmacy – or both? How can we best tackle diabetes and obesity? Are major policy changes coming soon? Read about our trip late last year to the International Diabetes Federation’s 21st World Congress in Dubai.

logbook

Diabetes on stage: Jim Hirsch tells us about Robbie McCauley’s powerful and revealing one-woman production, “Sugar,” that played in Boston in January…

sum musings

Kerri Morrone Sparling reflects on the true meaning of ‘need’ in the global diabetes community…

trial watch

Can metformin improve cardiovascular health and glucose control in people with type 1 diabetes? Will an early-stage artificial pancreas product effectively minimize both high and low blood glucose levels?

in this issue

Issue 39